sub:assertion {
  d:DB00619 v:identifier "DB00619" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB00619" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB00619> ;
    dv:drugbank-id "APRD01028" , "DB00619" , "DB03261" , "EXPT02967" ;
    dv:x-ahfs <http://bio2rdf.org/ahfs:10:00.00> ;
    dv:x-atc <http://bio2rdf.org/atc:L01XE01> ;
    dv:x-bindingdb <http://bio2rdf.org/bindingdb:13530> ;
    dv:x-cas <http://bio2rdf.org/cas:152459-95-5> ;
    dv:x-chebi <http://bio2rdf.org/chebi:45783> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:5101> ;
    dv:x-dpd <http://bio2rdf.org/dpd:2253283> ;
    dv:x-kegg <http://bio2rdf.org/kegg:D01441> ;
    dv:x-ndc <http://bio2rdf.org/ndc:0078-0401-34> ;
    dv:x-pdb <http://bio2rdf.org/pdb:STI> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA10804> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:5291> ;
    dv:x-pubchemsubstance <http://bio2rdf.org/pubchem.substance:46505055> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Imatinib> ;
    dct:description """Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.

It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells."""@en ;
    dct:identifier "drugbank:DB00619" ;
    dct:title "Imatinib"@en ;
    a dv:Drug ;
    rdfs:label "Imatinib [drugbank:DB00619]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB00619> , <http://www.drugs.com/cdi/imatinib.html> , <http://www.rxlist.com/cgi/generic3/gleevec.htm> .
}